TY - JOUR T1 - Efficacy of a patient isolation hood in reducing exposure to airborne infectious virus in a simulated healthcare setting JF - medRxiv DO - 10.1101/2022.07.24.22277784 SP - 2022.07.24.22277784 AU - Leo Yi Yang Lee AU - Shane A Landry AU - Milan Jamriska AU - Dinesh Subedi AU - Simon A Joosten AU - Jeremy J Barr AU - Reece Brown AU - Kevin Kevin AU - Robyn Schofield AU - Jason Monty AU - Kanta Subbarao AU - Forbes McGain Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/07/29/2022.07.24.22277784.abstract N2 - Background Healthcare workers treating patients with SARS-CoV-2 are at risk of infection from patient-emitted virus-laden aerosols. We quantified the reduction of airborne infectious virus in a simulated hospital room when a ventilated patient isolation (McMonty) hood was in use.Methods We nebulised 109 plaque forming units (PFU) of bacteriophage PhiX174 virus into a 35.1m3 room with a hood active or inactive. The airborne concentration of infectious virus was measured by BioSpot-VIVAS and settle plates using plaque assay quantification on the bacterial host Escherichia coli C. The particle number concentration (PNC) was monitored continuously using an optical particle sizer.Results Median airborne viral concentration in the room reached 1.41 × 105 PFU.m-3 with the hood inactive. Using the active hood as source containment reduced infectious virus concentration by 374-fold in air samples. This was associated with a 109-fold reduction in total airborne particle number escape rate. The deposition of infectious virus on the surface of settle plates was reduced by 87-fold.Conclusions The isolation hood significantly reduced airborne infectious virus exposure in a simulated hospital room. Our findings support the use of the hood to limit exposure of healthcare workers to airborne virus in clinical environments.Lay summary COVID-19 patients exhale aerosol particles which can potentially carry infectious viruses into the hospital environment, putting healthcare workers at risk of infection. This risk can be reduced by proper use of personal protective equipment (PPE) to protect workers from virus exposure. More effective strategies, however, aim to provide source control, reducing the amount of virus-contaminated air that is exhaled into the hospital room.The McMonty isolation hood has been developed to trap and decontaminate the air around an infected patient. We tested the efficacy of the hood using a live virus model to mimic a COVID-19 patient in a hospital room. Using the McMonty hood reduced the amount of exhaled air particles in the room by over 109-times. In our tests, people working in the room were exposed to 374-times less infectious virus in the air, and room surfaces were 87-times less contaminated. Our study supports using devices like the McMonty hood in combination with PPE to keep healthcare workers safe from virus exposure at work.Competing Interest StatementThe University of Melbourne and Western Health have a patent for the McMonty Hood. Forbes McGain and Jason Monty could receive royalties for sales of the McMonty isolation hood. The manufacturers of the McMonty hood had no role in the design of this study or manuscript preparation. All other authors have no conflicts of interest to declare.Funding StatementThis study was funded by a 2020 MRFF BioMedical Translation Bridge (BTBR 300182) Grant. Kanta Subbarao is supported by an NHMRC Investigator grant. The BioSpot VIVAS was purchased via a donation to the Royal Melbourne Hospital. The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. ER -